Virtual screening for oseltamivir-resistant a (H5N1) influenza neuraminidase from traditional Chinese medicine database: a combined molecular docking with molecular dynamics approach by Vasudevan Karthick & Karuppasamy Ramanathan
RESEARCH Open Access
Virtual screening for oseltamivir-resistant a (H5N1)
influenza neuraminidase from traditional Chinese
medicine database: a combined molecular
docking with molecular dynamics approach
Vasudevan Karthick and Karuppasamy Ramanathan*
Abstract
The neuraminidase (NA) of the influenza virus is the target of antiviral drug, oseltamivir. Recently, cases are reported
that Influenza virus becoming resistant to oseltamivir, necessitating the development of new long-acting antiviral
compounds. Most importantly, H274Y mutation in neuraminidase exhibits high levels of resistance to oseltamivir. In
this report, a novel class of lead molecule with potential NA inhibitory activity was found from the traditional
Chinese medicine database (TCMD) using virtual screening approach. Initially ADME properties of the lead
compounds were analyzed with respect to the Lipinski rule of five. Subsequently, the data reduction was carried
out by employing molecular docking study. Final validation was done by means of molecular dynamic simulations.
The toxicity profiles for the screened compound were also analyzed. The result indicates that neoglucobrassicin
(a compound derived from TCMD) become a promising lead compound and be effective in treating oseltamivir-resistant
influenza virus strains.
Keywords: Oseltamivir-resistance, Traditional Chinese medicine database (TCMD), Virtual screening, Molecular docking,
Molecular dynamic simulation
Introduction
Avian influenza A (H5N1) virus is highly pathogenic which
leads to high mortality rate in humans. Influenza A viruses
are enveloped RNA viruses with an eight-segmented,
single-stranded, belonging to the family Orthomyxoviridae
(Malik Peiris et al. 2009). Influenza viral membrane com-
posed of two main glycoproteins the hemagglutinin (HA)
and neuraminidase (NA) (Zhou et al. 2009). Based on
antigenic properties influenza type A viruses were classified
into 16 HA (H1–H16) and 9 NA (N1–N9) subtypes
(Gamblin & Skehel 2010). In humans influenza viruses
binds to cell sialic acid linked to galactose by an α-2,6 link-
age (SA α-2,6) (Malik Peiris et al. 2009). Hemagglutinin
(HA) is the receptor-binding and membrane fusion glyco-
protein of influenza virus and it contains two subunits
which have different functions. HA2 mediates fusion of
membrane and viral entry, while HA1 is involved in
binding to the sialic acid receptors on the target cell
(Skehel & Wiley 2000), and neuraminidase has sialidase
activity in which it cleaves sialic acid residues and facilitates
release of virus progeny by removing the terminal sialic
acids to which the HA binds (Stephenson & Democratis
2006).
Neuraminidase (NA) inhibition is a pivotal step in
restricting the spread of influenza virus infection in the
host. Oseltamivir (Tamiflu) and zanamivir (Relenza) are
two currently used NA inhibitors that were developed
using the knowledge of the enzyme structure. It has
been proposed that closer the inhibitors resemble the
natural substrate, the less likely they are to select drug-
resistant mutant viruses that retain viability. Oseltamivir
is the first line antiviral drug used for the treatment
against influenza and it is an active influenza neuramin-
idase inhibitor which is recommended for treating and
preventing influenza virus infection. However, there have
been reports of oseltamivir-resistant mutant selection
in vitro and from infected humans. In particular H274Y,
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the principal mutation isolated in association with
oseltamivir treatment that is specific to the N1 group
(Yen et al. 2007) and that has recently been shown to be
present in substantial numbers of H5N1 viruses isolated
from humans (Uyeki 2009). Virtual screening (VS) is a
widely used method that has been shown to be success-
ful in a variety of studies (Oprea & Matter 2004). In the
past few years, many reports indicated that virtual
screening techniques proved to be effective in making
qualitative predictions that discriminated active from in-
active compounds (Chen 2008; Chang et al. 2011a;
Chang et al. 2011b; Lin et al. 2011; Chang et al. 2011c;
Chang et al. 2011d). The basic goal of the virtual screen-
ing is the reduction of the enormous virtual chemical
space of small organic molecules, to synthesize and/or
screen against a specific target protein, to a manageable
number of the compound that inhibit a highest chance
to lead to a drug candidate.
The use of experimentally derived protein structures
and a hybrid computational method that combines the ad-
vantages of docking algorithms with dynamic structural
information provided by molecular dynamics simulation
techniques has been successfully applied to a number of
systems and most recently, aid in the discovery of HER2,
H1N1 and M2 inhibitors (Yang et al. 2011; Tsai et al.
2011; Lin et al. 2011a; Lai et al. 2011; Chang et al. 2011e;
Lin et al. 2011b). In addition, molecular dynamic simula-
tion could also be helpful in the analysis of mechanism of
drug resistance. Recently, we have identified the mechan-
ism of oseltamivir resistance by means molecular docking
and molecular dynamics approach (Karthick et al. 2012).
The available literature evidences suggests that two or
three Arginine residues (150 loop) surrounding the car-
boxylic group of NA inhibitors play a key role in orienting
and stabilizing various inhibitors (Russell et al. 2006). Our
computational approach also correlates well with the ex-
perimental evidences. It indicates that the existence of
intermolecular interactions in some of the key Arginine
residues present in the cavity of NA play a key role in sta-
bilizing the inhibitors (Karthick et al. 2012).
Hence, the goal of the present study is to screen a virtual
library of oseltamivir analogs, which fill also the cavity ad-
jacent to the active site, aiming at finding new potent NA
inhibitors of the avian influenza virus H5N1 with the
aid of Traditional Chinese medicine database (TCMD).
Therefore, a combined molecular docking and molecular
simulation approach has been applied to screen the poten-
tial molecule from TCM. TCM has been in use in China
for thousands of years and is still very prominent in med-
ical field today. TCM pays more emphasis on systemic
medication and subscribes medicines originated from nat-
ural herbs that give little or none side effects. Various re-
search have been done on studying Chinese herbal
medicine and studies suggest that it can aid in the cancer
treatments especially head and neck cancer (Tou & Chen
2012), solution for the stroke risk (Chang et al. 2011f;
Chen et al. 2011; Chen & Chen 2011) and also for the flu
treatment (Chang et al. 2011c; Chang et al. 2011d; Lin
et al. 2011a; Lai et al. 2011; Chang et al. 2011e; Lin et al.
2011b; Chang et al. 2011g). However, none of the earlier
study reported the lead compound for the drug resistant
target of influenza virus (H5N1).
With the emergence of oseltamivir-resistant influenza
virus infections, compounds with alternative binding
modes may be of great clinical implications. Hence, in this
work, a combined molecular docking and dynamics ap-
proach has been applied to screen the potential molecule
from TCM against the drug resistant target of NA by
employing oseltamivir as query. Hopefully, we have pro-
posed some useful candidates for H5N1 and put forward a
constructive concept of designing H5N1 inhibitors.
Materials and methods
Data set preparation
The native and mutant (H274Y) type coordinates of NA
were taken from the Brookhaven Protein Data Bank
(Berman et al. 2000). The corresponding PDB codes
were 2HU4 and 3CL0 respectively (Russell et al. 2006).
The structures were solved with 2.50 and 2.20 Å resolu-
tions, respectively, having residues from 83 to 468.
Oseltamivir was used as the small molecule/inhibitor for
our investigation. The SMILES strings were collected
from PubChem, a database maintained in NCBI (Feldman
et al. 2006), and submitted to CORINA for constructing
the 3D structure of the small molecule (Gasteiger et al.
1990). The three dimensional structure of target proteins
(2HU4 and 3CL0) and drug molecule were energy-
minimized using GROMACS package 4.5.3 (Hess et al.
2008; Spoel et al. 2005) adopting the GROMOS43a1 force
field parameters before performing the computational
analysis.
Virtual screening
Virtual screening (Shoichet 2004) is the computational
analogue of biological screening. The approach has be-
come increasingly popular in the pharmaceutical research
for lead identification. The basic goal of the virtual screen-
ing is the reduction of the massive virtual chemical space
of small organic molecules, to screen against a specific
target protein, to a manageable number of the compound
that inhibit a highest chance to lead to a drug candidate
(Tondi et al. 1999). We obtained 3D structure of osel-
tamivir in SDF format from PubChem database and we
submitted the structure in TCM database choosing simi-
larity option in order to get most similar structure of
oseltamivir (Chen 2011).
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ADME
Molecular properties such as membrane permeability and
bioavailability are always associated with some basic mo-
lecular descriptors such as logP (partition coefficient), mo-
lecular weight (MW), or counts of hydrogen bond
acceptors and donors in a molecule (Ertl et al. 2000).
These molecular properties were used in formulating “rule
of five” (Lipinski et al. 1997) The rule states that most
molecules with good membrane permeability have Mo-
lecular Weight ≤ 500, calculated octanol–water partition
coefficient, log P ≤ 5, hydrogen bond donors ≤ 5 and
acceptors ≤ 10 (Muegge 2003). Therefore, Lipinski’s Rule
of Five was used to test the bioavailability characteristics
such as absorption, distribution, metabolism, elimination
(ADME) of the lead compounds. In the present study,
these molecular properties for all the lead compounds
were estimated by using MOLINSPIRATION program
(2008).
Computation of docking energy
The lead compounds obtained from the virtual screening
analysis were used in the docking calculation. Flexible
docking simulation was performed using ArgusLab 4.0.1
(Thompson 2004). The ArgusLab 4.0.1 docking program
has been extensively validated with docking accuracy at
~3 Å, for root mean square deviation (RMSD) value
between the predicted and original crystallographic pose.
Flexible ligand docking of ArgusLab is available by de-
scribing the ligand as a torsion tree. Groups of bonded
atoms that do not have rotatable bonds are nodes, while
torsions are the connections between the nodes. Top-
ology of a torsion tree is a determinative factor influen-
cing efficient docking. In the docking calculations, the
scoring method Ascore from the ArgusLab 4.0.1 suite is
employed. AScore is based on the decomposition of the
total protein–ligand binding free energy, taking into
account the following contributions: the van der Waals
interaction between the ligand and the protein, the
hydrophobic effect, the hydrogen bonding between the
ligand and the protein, the hydrogen bonding involving
charged donor and/or acceptor groups, the deformation
effect, and the effects of the translational, and rotatio-
nal entropy loss in the binding process, respectively,
(Thompson 2004). The AScore function, with the pa-
rameters read from the AScore.prm file, was used to
calculate the binding energies of the resulting docked
structures. This file contains the coefficients for each
term in the scoring function. Each docking run was re-
peated five times to get the best results. A maximum
of 150 poses were allowed to be analyzed. Given the
imperfections of computational docking analysis, a re-
cent trend in this field has been the introduction of
Table 1 Calculations of molecular properties of oseltamivir and lead compound using Molinspiration
S. No Compounds miLogP MW nON nOHNH nrotb nviolations
1 Oseltamivir 0.852 315.38 6 3 8 0
2 Neoglucobrassicin −3.619 477.493 10 3 8 0
3 Acanthoglabrolide 3.502 418.486 7 0 7 0
4 Epifriedelanol Acetate 8.556 470.782 2 0 2 1
5 g-strophanthin −2.178 584.659 12 8 4 3
6 Allyl Propyl disulfide 2.86 148.296 0 0 5 0
7 Allyl monosulfide 2.127 114.213 0 0 4 0
8 Strictinin 0.312 634.455 18 11 3 3
9 Strophanthin −1.421 726.813 15 7 8 3
10 Acanthoside −1.475 742.724 18 8 12 3
Bold indicates ADME screened compounds based on Lipinski rule of 5.
Table 2 Comparison of free energy of binding between mutant type of NA with oseltamivir and virtual compounds
obtained from traditional Chinese medicine database
S.No Ligand
informations
Free energy of binding, ΔG (kcal/mol)
Wild type NA-Ligand complex Mutant type NA-Ligand complex
Docking 1 Docking 2 Docking 3 Avg Docking 1 Docking 2 Docking 3 Avg
1 Oseltamivir −8.62 −8.43 −8.22 −8.42 −7.72 −7.54 −7.21 −7.49
2 Neogleucobrassicin −10.48 −10.26 −10.37 −10.37 −8.5 −8.53 −8.72 −8.58
3 Acanthoglabrolide −6.45 −6.38 −6.43 −6.42 −7.22 −7.19 −6.98 −7.13
4 AllylPropyldisulfide −6.54 −6.76 −6.84 −6.713 −6.45 −6.434 −6.36 −6.414
5 Allyl monosulfide −6.04 −6.25 −6.534 −6.27 −6.0 −6.0 −6.0 −6.14
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re-dockings to evaluate the ligand binding affinity. The
results from these docking studiess were then combined
to balance the errors in the in silico prediction and this
kind of approach certainly improve the probability of
identifying ‘true’ ligands and helpful in the ligand bind-
ing analysis. For all docking analysis, the binding site
residues were retrieved from the program called ligand
Contact Tool (LCT) (Lopez et al. 2007) by employing
the NA-Oseltamivir complex structure as query. More-
over, literature evidences were also used to screen and
validate the active site residues (Colman et al. 1983).
LIGPLOT (Wallace et al. 1995) used to visualize the in-
teractions exists in the complex structures.
Molecular dynamics simulation
The crystal structure of wild NA-oseltamivir complex
(2HU4), mutant NA-oseltamivir complex (3CL0) and
docked complex of mutant-NA neoglucobrassicin complex
were used as starting point for MD simulation using
GROMACS package 4.5.3 (Hess et al. 2008; Spoel et al.
2005) adopting the GROMOS43a1 force field parameters.
The structures were solvated in cubic 0.9 nm, using
Figure 1 Docked poses of oseltamivir with wild (A, B and C) and mutant type NA (D, E and F).
Figure 2 Docked poses of neoglucobrassicin with wild (A, B and C) and mutant type NA (D, E and F).
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periodic boundary conditions and the SPC water model
(Meagher & Carlson 2005). PRODRG server (Schuttelkopf
& Van Aalten 2004) was used to generate ligand topology.
3Na + counter ions were added to neutralize the total
charge of the system. 1000 steps of steepest descent energy
minimization were carried out for the protein-ligand com-
plex. After energy minimization, the system was equili-
brated at 300 k. The equilibrated structures were then
subjected to molecular dynamic simulations for 5000 ps at
the constant temperature of 300 K and at the constant
pressure of 1 atm, and the integration time step was set to
2 fs. The non-bonded list was generated, using an atom-
based cutoff of 8 Å. The long range electrostatic interac-
tions were handled by the particle-mesh Ewald algorithm
(Darden et al. 1999). 0.9 nm cut-off was employed to
Lennard-Jones interaction. During the simulations, all
bond lengths containing hydrogen atoms were constrained
utilizing the Lincs algorithm (Lindahl et al. 2001), the tra-
jectory snapshots were stored for structural analysis at
every pico-second. Root mean square deviation (RMSD)
was analyzed through Gromacs utilities g_rmsd.
Toxicity
Successful drug discovery requires high quality lead struc-
tures which may need to be more drug-like than commonly
accepted (Proudfoot 2002). Toxicity and poor pharmaco-
kinetics should be eliminated in the early stages of drug dis-
covery. Hence, the hits were further screened using drug-
likeliness, drug score and toxicity characteristics. These
physico-chemical properties were therefore calculated for
the filtered set of hits using the programs (OSIRIS 2001).
The OSIRIS program calculates the drug likeliness
based on a list of about 5,300 distinct substructure frag-
ments created by 3,300 traded drugs as well as 15,000
Figure 3 The interaction of Oseltamivir (a) and Neoglucobrassicin (b) with wild type NA (PDB Code 2HU4).
Figure 4 The interaction of Oseltamivir (a) and Neoglucobrassicin (b) with mutant type NA (PDB Code 3CL0).
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commercially available chemicals yielding a complete list
of all available fragments with associated drug likeliness.
The drug score combines drug-likeliness, cLogP, logS, mo-
lecular weight, and toxicity risks as a total value which
may be used to judge the compound’s overall potential to
qualify for a drug.
Results and discussion
Virtual screening and bioactivity analysis
The new lead molecules were screened from using currently
active oseltamivir compound as template from the TCMD
and 9 compounds were founded. Pharmacokinetic & tox-
icity issues are blamed for more than half of the failure in
the clinical trials. Therefore in the first part of the virtual
screening evaluates the drug likeness of the same molecules
most independent of their intended drug target. The mo-
lecular properties and bioactivity for the lead compounds
were predicted using Molinspiration program (www.
molinspiration.com). The LogKow program (Remko 2009)
estimates the log octanol/water partition coefficient (logP)
of organic chemicals and drugs by an atom/fragment contri-
bution method developed at Syracuse Research Corporation
(Wang et al. 1997). Log P value is an important predictor of
per oral bioavailability of drug molecules (Clark 1999;
Chang et al. 2004). Therefore, we calculated log P values
along with other physiochemical properties such as molecu-
lar mass, the number of hydrogen bond acceptors and the
number of hydrogen bond donors for the all the 9 lead
compounds obtained from the TCM database. The results
showed that 4 molecules have zero violations of the Rule of
5 which suggest that these molecules likely to have good
bioavailability (Table 1). Hence, the subsequent analysis was
performed with the help of these screened molecules.
Molecular docking studies
The docking study employed to identify the binding affinity
of the molecule with the target proteins. However, standard
error in the scoring function could leads to the improper
selection of the lead compound. Thus, re-docking was
employed to eliminate the false positive in the screening
process. Then, X-ray crystallography structures of wild and
mutant type NA were retrieved from the Protein Data Bank
(PDB). The corresponding PDB ids are 2HU4 and 3CL0 for
the wild and mutant type of NA respectively. The binding
residues of the target structures were collected from
the available literature evidences (Colman et al. 1983;
Rungrotmongkol et al. 2009). Docking describes a process
by which small molecule and the active site of biological
macromolecule fit together in three-dimensional space and
has contributed important proceedings to drug discovery
for many years. Initially flexible docking simulation was
performed using ArgusLab 4.0.1 (http://www.ArgusLab.
com). We docked all the 4 molecules filtered from bioavail-
ability analysis to the wild (2HU4) and mutant type
of NA (3CL0) and the results were ranked by scoring
function. The results of molecular docking showed that
neoglucobrassicin, a compound obtained from Brassica
oleracea var. gongylodes, was identified because it ranked
first in the docking results (Table 2). Subsequently, re-
docking was performed to eliminate the false positive com-
pound from the results. The results were shown in Table 2
and the corresponding docked poses of NA-oseltamivir
complexes and NA-neoglucobrassicin complexes of both
wild and mutant type were shown in the Figures 1 and 2. It
is interesting to observe that the average binding energy of
NA-neoglucobrassicin is higher than NA-oseltamivir com-
plex in both wild and mutant type of NA.
LIGPLOT (Wallace et al. 1995) used to visualize the in-
teractions exists in the complex structures. The docking
conformation and the interacting pattern of oseltamivir
and neoglucobrassicin with wild and mutant type NA
were shown in Figures 3 and 4. It is evident from the fig-
ure that H274Y mutation alters the confirmations of the
NA binding pocket. As a result the number of interactions
Figure 5 Backbone root mean square deviations correspond to
wild-oseltamivir (black), mutant-oseltamivir (red) and mutant-
neoglucobrassicin (green) along the MD simulation at 300k.
Figure 6 Root mean square deviations correspond to ligand in
NA-ligand complexes: wild-oseltamivir (black), mutant-
oseltamivir (red) and mutant- neoglucobrassicin (green) along
the MD simulation at 300k.
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between oseltamivir with mutant type NA was reduced
and it leads to decrease in the binding affinity, thus confer
drug resistance. Despite the H274Y mutation in the struc-
ture of NA, neoglucobrassicin were retained the inter-
action with the residues R-371 and R-152 as like the wild
type NA. Furthermore, the existence of additional hydro-
gen bond in the residues R-292 and E-277 may also con-
tribute to the effective binding of NA-neoglucobrassicin
complex. Since there are several hydroxyl groups in
neoglucobrassicin, they have the potential to form hydro-
gen bonds with surrounding residues (Figure 4). Hence,
these extensive interactions are most important for the
stability of NA-neoglucobrassicin complex.
Molecular dynamics simulation
The ligand binding and the important macromolecular
motions associated with it are microscopic events that take
place in mere millionths of a second. Therefore, a complete
understanding of the atomistic energetics and mechanics
of binding is unattainable using current experimental tech-
niques. Molecular dynamics simulations are useful for
filling in the details where experimental methods cannot
Table 3 Toxicity risks and physicochemical properties of oseltamivir and virtual compounds predicted by OSIRIS
property explorer
S.No Compound Mutagenic Tumorigenic Irritant cLogP Solubility Drug likeness Drug score
1 Oseltamivir No No No 1.439 −2.448 −1.499 0.535
2 Neoglucobrassicin No No No 0.175 −4.006 −0.046 0.558
3 Epifriedelanol Acetate No No No 7.729 −7.327 −12.317 0.134
4 g-strophanthin No No No 2.138 −4.339 −0.327 0.422
5 Acanthoglabrolide Medium No High 4.405 −4.187 −12.317 0.134
6 AllylPropyl disulfide No No No 0.888 −2.767 −5.032 0.471
7 Allyl mono sulfide No No No 0.714 −2.671 −3.852 0.481
8 Strictinin No No No 0.89 −2.79 −2.836 0.284
9 Strophanthin No No High 1.105 −3.79 −3.276 0.239
10 Acanthoside No No No 1.787 −1.7 −1.884 0.259
Figure 7 Osiris property explorer showing drug likeness properties of Neoglucobrassicin.
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(Durrant & McCammon 2011). Hence, in the present
study molecular dynamic simulation was carried out by
GROMACS package 4.5.3 (Hess et al. 2008; Spoel et al.
2005) adopting the GROMOS43a1 force field parameters
which aimed to simulate the induced fit including potential
conformational movements of both the protein and the lig-
and. Results showed that the average atom especially atoms
of the NA-neoglucobrassicin complex movements were
small, fast convergence of energy and changes in geometry
as measured by Backbone RMSD analysis. Furthermore,
we have analyzed the RMSD profile of the ligand in the
protein-ligand complex structures to validate the stability
of the lead compound. The RMSD results indicate that
neoglucobrassicin movement is small in the mutant type of
NA structure than Oseltamivir in the mutant type of NA.
This is the indicative of neoglucobrassicin stability within
the binding pocket of mutant type NA (Figures 5 and 6).
This highlights the stable binding of the neoglucobrassicin
with wild and mutant type NA.
Toxicity and physicochemical properties
Many drug candidate fail in the clinical trials reasons is
unrelated in the potency against the intended drug target.
Pharmacokinetic and toxicity issues are blamed for more
than half of all failure in the clinical trials. Therefore it is
essential to evaluates Pharmacokinetic and toxicity of
small molecules.
The parameter clogP and logS were assessed to analyze
the pharmacokinetic property of the filtered set of com-
pounds. clogP is a well-established measure of the com-
pound’s hydrophilicity. Low hydrophilicities and therefore
high log P values may cause poor absorption or permeation.
It has been shown for compounds to have a reasonable
probability of being well absorb their logP value must not
be greater than 5.0. On this basis, neoglucobrassicin have
log P values in the acceptable criteria.
Drug solubility is an important factor that affects the
movement of a drug from the site of administration into
the blood. It is known that insufficient solubility of drug
can leads to poor absorption (Muegge 2003). Our estimated
log S value is a unit stripped logarithm (base 10) of a com-
pound’s solubility measured in mol/liter. There are more
than 80% of the drugs on the market have an (estimated)
log S value greater than −4. Table 3 shows solubility of
oseltamivir and other virtual compounds. It is clear from
the table that the solubility of neoglucobrassicin was found
in the comparable zone with that of standard drugs to fulfill
the requirements of solubility and could be considered as a
candidate drug for oral absorption.
Drug likeness
The drug likeliness is another important parameter. Be-
cause drug like molecules exhibit favorable absorption, dis-
tribution, metabolism, excretion, toxicological (ADMET)
parameters. Currently, there are many approaches to assess
a compound drug-likeness based on topological descrip-
tors, fingerprints of molecular drug-likeness structure keys
or other properties such as clog P and molecular weight
(Tetko 2005). In this work, Osiris program (Sander) was
used for calculating the fragment-based drug-likeness of of
oseltamivir and other virtual compounds. The drug-
likeness value of neoglucobrassicin was found to be in ac-
ceptable criteria.
Toxicity
The toxicity risk predictor locates fragments within a mol-
ecule, which indicate a potential toxicity risk. Toxicity risk
alerts are an indication that the drawn structure may be
harmful concerning the risk category specified. From
the data evaluated in Table 3 indicates that the allyl
propyldisulfide, allyl monosulfide and neoglucobrassicin
non-mutagenic, non-irritating with no Tumorigenic ef-
fects when run through the mutagenicity assessment sys-
tem comparable with standard drugs used.
Drug score
We have also examined the overall drug score (DS) for all
the neoglucobrassicin and compared with that of standard
drugs Oseltamivir. The drug score combines drug likeness,
miLogP, log S, molecular weight and toxicity risks in one
handy value than may be used to judge the compound’s
overall potential to qualify for a drug. The result is shown
in Table 3. Neoglucobrassicin showed good DS as com-
pared with other lead molecules and standard drug used.
The toxicity, drug-likeness and drug-score results for the
neoglucobrassicin were illustrated in Figure 7.
Conclusion
Neoglucobrassicin is a compound extracted from TCMD
was predicted to be more potent inhibitor of NA than the
existing drugs such as Oseltamivir. Favorable binding in-
teractions with wild and mutant type of NA have been ob-
served through an extensive docking study. Furthermore,
RMSD analysis observed during MD simulation results
certainly indicates the stable binding of neoglucobrassicin
with NA structures. Moreover, neoglucobrassicin com-
pound is based on natural product metabolites and are
not expected to have undesirable side effects as the trad-
itional drugs. This is also confirmed from our ADME and
toxicity studies. We believed that the findings reported
here might provide useful clues for designing powerful
drugs against drug resistant target of NA.
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